We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AbbVie has prevailed in a lawsuit alleging that it violated antitrust laws by exploiting the patent system and making deals with companies for its blockbuster drug Humira (adalimumab). Read More
Researchers funded by the National Institutes of Health (NIH) are evaluating drugs doctors are using to treat COVID-19 in infants, children and adolescents. Read More
Partly in response to the COVID-19 pandemic, HHS is partnering with a Boston-based drugmaker to create a domestic supply chain that doesn’t rely on foreign sources for active pharmaceutical ingredients. Read More
Anthony Fauci, director of the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), said that forcing price controls on pharmaceutical companies developing COVID-19 products will drive them away, expressing optimism that drugmakers will do the right thing on their own. Read More
The U.S. government is planning to launch phase 3 trials of three COVID-19 vaccine candidates, starting with Moderna’s as soon as next month, followed by AstraZeneca’s AZD1222 in August, and a Johnson & Johnson candidate in September. Read More
The average inspection score for pharma manufacturing sites in fiscal 2019 dropped slightly from the year before, but scores for over-the-counter and homeopathic products significantly dragged down the global average, says a new FDA report. Read More
Aimmune Therapeutics said that 80 percent of allergic patients in a trial of its oral immunotherapy Palforzia (peanut allergen powder-dnfp) were desensitized to peanut proteins. Read More
AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19. Read More